◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 4880

CellSource Co., Ltd. (4880) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-11

CellSource Co., Ltd. (4880) operates in the Biotechnology industry and is headquartered in Shibuya, Japan with about 148 employees. Its market capitalization is roughly JPY 7 billion. In the fiscal year ended 2025-10-31, 4880 reported JPY 3.7B in revenue and JPY 11M in net income.

CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan.

Interactive charts & full statements →

4880 Revenue & Earnings History — Annual Income Statement

Income statement2025-10-312024-10-312023-10-312022-10-312021-10-31
Total RevenueJPY 3.7BJPY 4.4BJPY 4.5BJPY 4.3B
Gross ProfitJPY 2.1BJPY 2.4BJPY 3.2BJPY 3.1B
Operating Income (EBIT)JPY 167MJPY 129MJPY 1.2BJPY 1.6B
Net IncomeJPY 11MJPY 238MJPY 923MJPY 1.0B

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

4880 Free Cash Flow History

Cash flow2025-10-312024-10-312023-10-312022-10-312021-10-31
Dividends Paid(JPY 99M)(JPY 394M)

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

4880 Balance Sheet History

Balance sheet2025-10-312024-10-312023-10-312022-10-312021-10-31
Total AssetsJPY 7.0BJPY 7.1BJPY 6.9BJPY 4.6B
Total LiabilitiesJPY 1.0BJPY 1.0BJPY 678MJPY 814M

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 4880 viewer.

Other Companies in Biotechnology

← 4875All “0-9” companies4885 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.